Deutsche Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,015
Eli Lilly Is Maintained at Buy by Deutsche Bank
Eli Lilly Analyst Ratings
Redburn Atlantic Adjusts Price Target on Eli Lilly to $700 From $640, Maintains Neutral Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $975
Deutsche Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,015
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $994
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $970 to $1,146
Barclays Maintains Overweight on Eli Lilly, Lowers Price Target to $975
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $975 to $1,100
Eli Lilly Is Maintained at Buy by B of A Securities
Eli Lilly Analyst Ratings
Jefferies Adjusts Price Target on Eli Lilly to $994 From $1,113, Maintains Buy Rating
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Eli Lilly Analyst Ratings
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $990
No Data
No Data